Literature DB >> 19828742

Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii.

Alexandros Ikonomidis1, Evangelia Neou, Vassiliki Gogou, Georgia Vrioni, Athanassios Tsakris, Spyros Pournaras.   

Abstract

The characteristics of carbapenem heteroresistance were studied in 14 apparently carbapenem-susceptible Acinetobacter baumannii isolates. The MICs for carbapenems were determined, and the isolates were genotyped by pulsed-field gel electrophoresis (PFGE) and sequence typing (ST). Population analysis, testing of the stability of the heteroresistant subpopulations, and time-killing assays were performed. The agar dilution MICs of both imipenem and meropenem for the native isolates ranged from 0.25 to 4 mg/liter. The isolates belonged to nine PFGE types and exhibited seven ST allelic profiles. Population analysis revealed subpopulations that grew in the presence of imipenem at concentrations of up to 8 mg/liter and meropenem at concentrations of up to 32 mg/liter. The meropenem-heteroresistant subpopulations of 11 isolates exhibited stable resistance with MICs that ranged from 16 to >32 mg/liter; their PFGE profiles were identical to those of the native isolates. Time-kill assays with meropenem revealed less pronounced killing for 10 isolates. These findings indicate that meropenem pressure can produce meropenem-heteroresistant subpopulations that might subsequently select for highly resistant strains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828742      PMCID: PMC2786618          DOI: 10.1128/JCM.00959-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.

Authors:  Chen-Hsiang Lee; Lin-Hui Su; Ya-Fen Tang; Jien-Wei Liu
Journal:  J Antimicrob Chemother       Date:  2006-09-13       Impact factor: 5.790

2.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase.

Authors:  Mariana Castanheira; Mark A Toleman; Ronald N Jones; Franz J Schmidt; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit.

Authors:  S Pournaras; A Markogiannakis; A Ikonomidis; L Kondyli; K Bethimouti; A N Maniatis; N J Legakis; A Tsakris
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

5.  Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species.

Authors:  Jane F Turton; Neil Woodford; Judith Glover; Susannah Yarde; Mary E Kaufmann; Tyrone L Pitt
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea.

Authors:  Kyungwon Lee; Jong Hwa Yum; Dongeun Yong; Hyuk Min Lee; Heung Dong Kim; Jean-Denis Docquier; Gian Maria Rossolini; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

7.  Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

Authors:  George Sakoulas; Jeff Alder; Claudie Thauvin-Eliopoulos; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

8.  Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England.

Authors:  Juliana M Coelho; Jane F Turton; Mary E Kaufmann; Judith Glover; Neil Woodford; Marina Warner; Marie-France Palepou; Rachel Pike; Tyrone L Pitt; Bharat C Patel; David M Livermore
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

9.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

10.  Appearance of resistance to meropenem during the treatment of a patient with meningitis by Acinetobacter.

Authors:  M L Núñez; M C Martínez-Toldos; M Bru; E Simarro; M Segovia; J Ruiz
Journal:  Scand J Infect Dis       Date:  1998
View more
  12 in total

Review 1.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae.

Authors:  Spyros Pournaras; Ioulia Kristo; Georgia Vrioni; Alexandros Ikonomidis; Aggeliki Poulou; Dimitra Petropoulou; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

3.  Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.

Authors:  Carole Shubert; Jen Slaughter; David Creely; Alex van Belkum; Jean Pierre Gayral; William Michael Dunne; Gilles Zambardi; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 4.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

5.  Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae.

Authors:  Sheila Adams-Sapper; Shantell Nolen; Grace Fox Donzelli; Mallika Lal; Kunihiko Chen; Livia Helena Justo da Silva; Beatriz M Moreira; Lee W Riley
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

6.  Heteroresistance to cephalosporins and penicillins in Acinetobacter baumannii.

Authors:  Kuei-Hsiang Hung; Ming-Cheng Wang; Ay-Huey Huang; Jing-Jou Yan; Jiunn-Jong Wu
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

7.  Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Rachel L Soon; Justin R Lenhard; Zackery P Bulman; Patricia N Holden; Pamela Kelchlin; Judith N Steenbergen; Lawrence V Friedrich; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

8.  Research of the heteroresistance of Pseudomonas aeruginosa to imipenem.

Authors:  Shencong Mei; Yulu Gao; Changtai Zhu; Chunlei Dong; Yawen Chen
Journal:  Int J Clin Exp Med       Date:  2015-04-15

9.  Carbapenem Heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing.

Authors:  M Tato; M Morosini; L García; S Albertí; M T Coque; R Cantón
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

10.  Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?

Authors:  Cristina García-Salguero; Iciar Rodríguez-Avial; Juan J Picazo; Esther Culebras
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.